America’s amputation crisis (Part 3 of 4): Following the money behind the amputation epidemic

The Disturbing Economics Behind America’s Amputation Epidemic

In my years as a patient advocate, I’ve had countless conversations with healthcare executives about the economics of limb preservation versus amputation.

During one particularly candid exchange at a healthcare conference, a hospital administrator admitted something that continues to haunt me:

“Amputations are more profitable, more predictable, and take less OR time.”

This uncomfortable truth rarely reaches patients: behind America’s amputation epidemic lie powerful financial incentives that favor limb removal over limb preservation. To be clear, not all hospitals take this approach—many excellent medical centers prioritize limb preservation whenever possible. But within our fragmented healthcare system, the economics create disturbing incentives that work against patient interests.

Advanced PAD: When limbs are at stake

For those just joining this series, I’m focusing specifically on advanced peripheral artery disease (PAD), which is poor circulation in mainly the leg arteries, not the early stages where patients experience pain only when walking that’s relieved at rest. I’m talking about the often-missed, advanced stages where patients, particularly those with chronic kidney disease and diabetes, face imminent limb loss. These patients typically don’t present with traditional PAD symptoms of intermittent claudication, meaning that when they walk they experience leg cramps that are relieved at rest. Instead, they often initially arrive in late stage PAD, known as Critical Limb Ischemia (CLI), with severe pain that wakes them at night, non-healing wounds, or gangrene—signs that their limbs are already threatened and immediate intervention is needed.

The economics of treating these patients reveals a healthcare system at war with itself. According to a preliminary economic model published in the Journal of Vascular Surgery, an amputation costs approximately $30,000 to $40,000 in immediate surgical expenses, with lifetime costs—including prosthetics, rehabilitation, home modifications, and lost productivity—often exceeding $500,000 per patient. In stark contrast, advanced limb salvage procedures typically cost between $10,000 and $20,000. Even accounting for potential reinterventions, the cost-benefit analysis overwhelmingly favors attempting limb preservation first, as another study in the Journal of Vascular Surgery examining socioeconomic and hospital-related predictors of amputation confirms.

So why would our healthcare system consistently favor the more expensive, less patient-friendly option? To answer this question, we need to follow the money.

The hidden economics: Lifetime costs of amputation

The full economic picture of amputation extends far beyond the initial surgical costs. Patients who undergo major lower extremity amputations face prosthetic costs averaging $5,000-$50,000 per device (with replacements needed every 3-5 years), home modifications averaging $20,000-$30,000, lost productivity averaging $43,000 annually for working-age patients, and increased need for assisted living or nursing home care. Health economists estimate the lifetime societal cost of preventable amputations exceeds $100 billion annually when accounting for all direct and indirect costs, according to research published by Driver and colleagues in the Journal of Vascular Surgery.

This staggering figure raises the obvious question: if the economic case for limb preservation is so compelling, why does our system continue favoring amputation? The answer lies in how healthcare costs and benefits are distributed across our fragmented system. While the total cost of amputation far exceeds limb preservation, these costs are spread across multiple payers:

• The initial amputation costs fall to the primary insurer
• Prosthetic costs may be shared between insurers and patients
• Lost productivity costs fall primarily on patients and employers
• Long-term care costs may shift to Medicaid after patients exhaust personal resources
• Disability costs fall to Social Security and other government programs

This fragmentation creates a classic “tragedy of the commons” scenario where no single entity bears the full economic consequence of unnecessary amputations. Each actor optimizes for their portion of the cost structure rather than considering the overall societal impact, as described in an analysis by Yost in Endovascular Today.

For insurance companies in particular, these long-term costs can be avoided entirely through one disturbing reality: the high mortality rates following amputation.

When patient death improves profit margins: The insurance company calculus

Let’s address perhaps the most disturbing explanation for our amputation epidemic. Why would insurance companies prefer the more expensive option? The answer becomes clearer when examining what happens after amputation. Research shows that patients who undergo major amputations face dramatically higher mortality rates—one-year mortality between 38.3% to 40%, with rates exceeding 60% by three years post-amputation, according to multiple studies including work by Jones and colleagues published in the American Heart Journal.

For insurers, particularly in short-term commercial coverage models, a patient who dies within a year or two of amputation represents hundreds of thousands in avoided long-term care costs we just examined. The cold calculation becomes: pay $40,000 for an amputation now, or risk ongoing treatments for a patient with multiple chronic conditions who might live for years with an intact limb.

This calculation becomes even more explicit in Medicare Advantage plans, where insurers receive capitated payments for each enrolled patient. For these insurers, minimizing overall care costs—even through higher mortality—directly improves profit margins, as suggested by a 2022 study in JAMA by Meyers and colleagues that found concerning differences in outcomes between Medicare Advantage and Traditional Medicare patients. The financial incentives tied to patient mortality represent the dark underbelly of our healthcare system that few are willing to acknowledge openly.

The perverse reality is that a patient who dies shortly after amputation may represent a “financial success” in insurance company actuarial models. This certainly isn’t on a conscious human level, but the reality on paper.

The hospital perspective: Time, resources, and predictability

For hospitals, the financial incentives similarly favor amputation, but for different reasons. Complex limb salvage procedures require longer operating room time (often 5+ hours versus 2 hours for amputation), more expensive specialized equipment, higher levels of technical expertise, and potentially longer hospital stays with more complications. In an environment where operating room efficiency directly impacts the bottom line, a straightforward amputation becomes far more attractive from a resource management perspective.

A Journal of Vascular Surgery analysis by Barshes and colleagues found that while limb salvage led to better patient outcomes, the resource utilization and financial returns often favored amputation in fee-for-service models. One vascular specialist in Florida recently told me that while he has the technical ability to open small arteries in the feet to save limbs, he often doesn’t attempt it because “there’s no reimbursement code for treating the pedal plantar artery loop in the foot.” Without a billing code, there’s no payment—so when these critical vessels are blocked, patients get sent to amputation instead.

This creates a perfect storm where both insurers and hospitals have financial incentives that align against limb preservation—insurers through payment structures that favor short-term costs over long-term outcomes, and hospitals through resource allocation pressures that favor predictable, shorter procedures.

The insurance playbook: Creating barriers to limb preservation

Ultimately, it all comes down to what the insurance companies will cover, however. And it doesn’t look like insurance companies are going to shift their priority from amputation to limb salvage anytime soon. At first in addressing this crisis in care coverage, the focus was on overcoming delays in case, then it progressed to flat-out denials. But now, what’s even more troubling is that, instead of following through on recent agreements with HHS Secretary RFK Jr. to minimize pre-authorization barriers, insurance companies are simply dropping physicians who specialize in these limb-saving procedures from their networks entirely. This effective elimination of specialists represents a disturbing evolution—one that circumvents any promise of streamlining approvals by removing patient access to qualified providers in the first place.

Healthcare attorneys representing physician groups have documented cases where insurers systematically identify and remove high-volume limb salvage specialists during contract renewals, citing “network adequacy” even when no other physicians in the region perform these specialized procedures, according to a 2023 survey by the American Medical Association’s Advocacy Resource Center. This leaves patients with no in-network options for limb preservation, effectively forcing them toward providers who lack the expertise to attempt complex revascularization—often hospital-based physicians who are already incentivized to choose amputation due to resource constraints.

These tactics create a vicious cycle: insurance companies restrict access to limb-saving specialists, sending patients to hospitals where resource limitations favor amputation, resulting in higher amputation rates that insurers then use to justify further restrictions on limb salvage procedures.

The amputation belt: How financial incentives create disparities

These financial incentives manifest in stark geographic and demographic patterns. Research by Goldberg and colleagues published in the Journal of Vascular Surgery has identified an “amputation belt” stretching across the southern United States where amputation rates exceed the national average by 300-500%. These disparities cannot be explained by disease prevalence alone. Even controlling for risk factors like diabetes and smoking, amputation rates vary dramatically based on race, insurance status, geographic location, and socioeconomic status. Black Americans face amputation rates four times higher than white Americans with the same disease severity, according to Lefebvre and Lavery’s analysis in Clinical Orthopedics and Related Research, while Medicaid patients face rates 47% higher than those privately insured, as documented by Hughes and colleagues in Vascular Medicine.

This geographic pattern directly correlates with areas where:

• Insurance networks have fewer specialized limb salvage providers
• Hospitals face greater resource constraints and financial pressures
• Patients have less access to second opinions and specialized care

The result is a self-reinforcing system where financial incentives create disparities that further entrench those same incentives. Areas with higher amputation rates typically have fewer specialists capable of complex limb salvage, which means more patients undergo amputation, which leads to a perception that amputation is the standard of care in those regions.

Yet these patterns aren’t inevitable. Dr. Foluso Fakorede demonstrated this when he opened a dedicated limb salvage center in the Mississippi Delta—a region with historically high amputation rates. His team reduced amputations by over 87% in just three years, proving most of these amputations were never medically necessary, as documented in Vascular Disease Management. They resulted from lack of access to appropriate care, not from medical necessity.

Deb’s story: The human impact of financial incentives

The human impact of these financial calculations becomes clear through the stories of patients like Deb from Georgia. She arrived at an emergency room with excruciating leg pain that woke her up at night. Without a comprehensive vascular evaluation or attempts at limb-saving procedures, the surgeon informed her she needed an amputation—scheduled for the very next morning.

While waiting for pre-surgical preparations, Deb found our support group and called our Leg Saver Hotline in desperation. Our patient navigators determined her life wasn’t immediately threatened and she had no open wounds on her feet. With our guidance, Deb declined the immediate amputation. The next day, we connected her with a vascular specialist who discovered a blockage in the artery behind her knee—one that could be opened with minimally invasive techniques.

Here’s where the insurance paradox became crystal clear: The insurer had readily approved the amputation the previous day—despite no wounds on her feet or acute life-threatening situation. Yet they required pre-authorization and delayed the less expensive, limb-saving procedure because she “didn’t have a wound on her foot” despite advanced stage limb-threatening ischemia with rest pain waking her up out of a sound sleep at night.

For two excruciating weeks, the doctor fought through multiple peer-to-peer reviews while Deb suffered at home. Our PAD navigators coached her through nights of torturous pain—what she described as “the worst charlie horse you could imagine”—helping her dangle her feet over the bed and offering emotional support through the ordeal.

Ultimately, the procedure was approved. Two years later, Deb remains on her feet. But her case perfectly illustrates the perverse incentives at play: immediate approval for a $40,000 amputation, yet weeks of denials for a $15,000 procedure that ultimately preserved both limb and life.

The insurance company calculus ignores what any patient would tell you: “I’d rather you give it the grand old try to save my leg versus taking the lazy way out and just cutting it off, even if it means multiple procedures.”

Shouldn’t healthcare be about improving the quality of life for patients?

The human cost of financially-driven amputations

Dawn, a patient who underwent amputation despite efforts to save her leg, offers insights that physicians and insurers rarely discuss with patients beforehand.

“Doctors don’t realize the struggles patients face trying to learn how to live again,” Dawn told me. “They said I’d be on my feet within six months with a prosthetic, but two years later, I still don’t have the right fitting because of insurance denials and delays in approving the best one for me.”

The indignities are relentless and deeply personal. “If you have to use the restroom, how many times you end up not making it because hopping over triggers leakage,” she explained. “When I had the stomach flu, I had to use puppy pads because I couldn’t make it to the bathroom in time.”

Beyond these practical challenges lies profound psychological trauma. “The grief of loss is much like losing a family member,” Dawn says. “And then there’s phantom pain—imagine pain in a leg that’s not even there anymore,” echoing findings from a comprehensive review by Horgan and MacLachlan in Disability and Rehabilitation that documented the extensive psychological challenges following amputation.

When mortality isn’t just a statistic

The mortality statistics associated with amputation become even more sobering when considering real people. One of my father’s military friends, a chronic kidney disease patient, underwent amputation without any attempt to save his leg through revascularization. During rehabilitation, his remaining leg began to deteriorate due to decreased mobility. Rather than endure a second amputation, he chose hospice care and died within weeks.

Similarly, a long-time family friend with diabetes had an amputation where the physician never attempted to open his arteries below the knee. In rehabilitation, his other leg also began failing due to reduced mobility. After a second amputation, he died within three months.

These aren’t isolated cases. Research published in the Journal of the American Heart Association shows that approximately 3 in 5 heart attack sufferers have PAD. When vascular disease is present, cardiovascular disease typically coexists. Without mobility, cardiovascular decline accelerates dramatically, often leading to premature death, as Armstrong and colleagues documented in their study.

This pattern raises a disturbing question I’ve thought about repeatedly during sleepless nights advocating for patients: Do insurance company actuaries factor these mortality statistics into their financial models? Are they effectively calculating that many of these patients will no longer be on their books within 12-18 months following amputation? Following the money trail suggests this might be precisely what’s happening. Although, I really can’t imagine this is on a conscious level. Again, it’s more likely at a faceless number crunching level.

Looking ahead: Breaking the financial cycle

As this series has shown, America’s amputation crisis is primarily driven by perverse financial incentives that favor limb removal over limb preservation, even unintentionally. These incentives permeate every level of our healthcare system—from insurance payment policies to hospital resource allocation—creating a self-reinforcing cycle that disproportionately harms our most vulnerable populations.

The $100 billion annual cost of preventable amputations represents not just an economic burden but a profound human tragedy—thousands of Americans facing disability, dependency, and premature death that might have been avoided with appropriate care.

In the final article of this series, I’ll examine comprehensive solutions that could dramatically reduce unnecessary amputations across America—from policy reforms and reimbursement changes to innovations in care delivery that could transform how we approach limb preservation.

Because in a healthcare system truly centered on patient needs, preserving limbs and lives would always take precedence over preserving profits.

For a list of article citations, email info@padhelp.org.